Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
These Lynparza website pages were funded and produced by AstraZeneca UK and MSD UK
*To be eligible for Lynparza + bevacizumab as maintenance, patients are required to have a complete or partial response to 1L platinum-based chemotherapy plus bevacizumab.1
† The licenced dose of bevacizumab is 15 mg/kg Q3W with carboplatin and paclitaxel for up to six cycles, followed by 15 mg/kg Q3W as a single agent, for a total of up to 22 cycles or until
unacceptable toxicity, whichever occurs earlier.1,3,4
*For concomitant administration with CY3PA inhibitors, or use in patients with hepatic or renal impairments, please consult the Lynparza 100 mg and 150 mg tablet Summary of Product Characteristics.
Resources
Discover our resources to support you and your patients
Contact us
or sign up to our mailing list
Please consult the SmPC for further information before making any prescribing decisions.
GB-73637 | February 2026
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.